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ABSTRACT
In 2016, the proportion of HIV-infected persons in the Baltic countries was 
as follows: Latvia 18.5, Estonia 17.4, Lithuania 7.4 per 100,000 of popula-
tion. The aim of our study was to evaluate the spectrum and morphology 
of combined lung pathologies in fatal HIV/AIDS cases in Latvia from 2010 
to 2016. We did a retrospective review of the HIV/AIDS patients’ medical 
autopsy case files and histological slides at the Pathology Centre of Riga 
Eastern Clinical University Hospital. All statistical data were processed in 
IBM SPSS Statistics 23. We analysed 455 cases – 311 (69%) men, 134 (31%) 
women. The mean age of the analysed patients was 40 years (±9 SD, range 
22–68). The conditions leading to death were opportunistic infections (OI) – 
28%, tuberculosis (TB) – 23%, wasting syndrome complicated by nonspecific 
pneumonia and sepsis or HIV/AIDS unrelated conditions – 27%, malignan-
cies – 11% (B large cell lymphoma, primary and secondary cancers of the 
lung, Kaposi sarcoma), and end stage liver disease – 11%. Lungs were affected 
in 380 cases (83.5%). We identified 112 cases of tuberculosis (TB). In 21%, 
it was isolated pulmonary TB, in 79% – disseminated TB. Additionally, OI 
were proved in 26% of these patients. The prevalence of OI was higher in 
patients who died from isolated pulmonary TB. We also identified 10 cases 
of disseminated atypical mycobacteriosis. Opportunistic infections were diag-
nosed in 126 persons  – 77% (n=97) of them had one, but 23% (n=29) had 
two or more OIs. The most common isolated OI with lung involvement was 
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Pneumocystis jiroveci (PC) pneumonia (n=71, 15.6%); 10% had cryptococ-
cosis, 1% – pulmonary aspergillosis and Candida pneumonia each. 40 patients 
(9%) had disseminated cytomegalovirus (CMV). Among the various combi-
nations of oppor tunistic infections, the most common was PC+CMV. 81% 
of HIV patients were unemployed and prisoners with interrupted treatment. 
We concluded that our study revealed that combined opportunistic infections 
and TB were the most frequently observed pulmonary infections, followed by 
primary and secondary lung malignancies and bacterial pneumonia in HIV/
AIDS  unrelated cases of multiorgan disease. Diagnostic difficulties occurred 
mainly in disseminated diseases due to nonspecific clinical presentation, 
similar appearance on  imaging studies and limited bacterial diagnostic possi-
bilities after death. 
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INTRODUCTION
In the present decade Latvia and Estonia have been among the European Union 
countries most heavily aff ected by the HIV/AIDS epidemic (Fig. 1). Th e main 
HIV transmission routes in Latvia are heterosexual contacts (40%) and IVDU 
(25%), but in 35% of cases the route of transmission is not reported [18, 37]. In 
Lithuania and Estonia, the situation is similar [5, 10, 20]. Practitioners, radio-
logists and pathologists in the 21st century – 35 years aft er the year 1982 when 
WHO accepted the word “AIDS” – are diagnosing very diff erent lung diseases 
in HIV-infected persons. If we look at the past, in 1982 98% of  respiratory 
complications were infectious in the USA [16]. HIV/AIDS-associated infec-
tions encountered in the WHO European Region include tuberculosis, bacte-
rial infections, Pneumocystis jiroveci (PC) pneumonia, herpes infections, 
Figure 1. Newly 
diagnosed HIV cases 
in the Baltic states in 
2010–2016.
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candida, cryptococcosis, toxoplasmosis, and Mycobacterium avium complex 
disease [14, 19]. Involvement of two or more noncontiguous visceral organs 
is considered disseminated disease [14]. In 2015, PC was among the most 
common AIDS-defi ning diseases diagnosed in the EU with the prevalence of 
20%, followed by tuberculosis (14%) and HIV wasting syndrome (11%) [24, 32, 
33]. Commonly, PC pneumonia is associated with CMV pneumonitis [2, 11]. 
Cryptococcosis occurs at a CD4 count below 100 cells/μl. Th e etiologic agent 
Cryptococcus neoformans is encountered in nature with a worldwide distribu-
tion; its site of entry is the respiratory tract [9]. In the case of a disseminated 
disease, the infl ammatory reaction is typically weak because a disseminated 
disease is rapidly fatal and no signifi cant cellular reaction can develop [8, 9].
Pulmonary aspergillosis is a ubiquitous opportunistic fungus. Th e classic 
risk factors for this infection – neutropenia and corticosteroid use – are not 
always present [4]. Aspergillus can also colonize pre-existing pulmonary cavi-
ties in the case of tuberculosis, Pneumocystis jiroveci pneumonia or necrotizing 
bacterial pneumonia [12, 28]. Opposite Candida pneumonia is a result of aspi-
ration from oral mucosal lesions or hematogenous spread. In the latter case, the 
lesions are miliary, bilateral, involving the pleura. Disseminated multi-organ 
disease, a result of vascular invasion, is uncommon but highly lethal [1, 13, 30]. 
Cytomegalovirus (CMV) causes localized pulmonary or disseminated 
invasive disease in AIDS [26]. Pre-ART (antiretroviral therapy) era studies, 
including autopsy-based, reported that CMV disease was recognized in end-
stage AIDS patients before death in up to 40% and at autopsy in up to 90% at 
that time [30]. Since the introduction of ART, CMV incidence and the related 
mortality among AIDS patients have declined. In ART era, patients who have 
CMV disease either do not receive or have failed to respond to antiretroviral 
therapy. Some authors suggest that CMV infection accelerates AIDS progres-
sion [26]. Mostly CMV disease is a result of reactivation of latent infection due 
to the fact that 50%–90% of adult general population depending on the world 
region are seropositive, as CMV and HIV share transmission routes [26, 30, 36]. 
Lungs can also be affected by Mycobacteriosis avium intracellulare. 
 “Atypical” mycobacteria are ubiquitous environmental organisms found in 
soil and water. Th e disease is acquired through ingestion or inhalation of 
the organism but is not spread from person to person [25]. Macrophages fail 
to organize immune response and, instead of arranging a granuloma, they 
pro liferate chaotically and place themselves in sheets which may totally obscure 
normal tissue structures. Langhans giant cells are absent or rare [3, 4].
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A co-infection of HIV is tuberculosis (TB), but it is not specifi c to HIV/
AIDS but common among these patients in endemic areas. HIV/AIDS patients 
are at high risk for a new TB infection, reinfection or reactivation. Pathoge-
netic relationships of HIV and TB are such that coinfection accelerates the 
natural course of both diseases [4]. In 2015 the proportion of HIV/TB patients 
in Latvia was 17.4% (in Estonia 12.4% and in Lithuania 3.6%). In the EU on 
average, this rate was 4.6% [5]. In advanced stages of HIV course, cavitary TB 
is uncommon and lower-lobe infi ltrates or miliary dissemination as well as 
extrapulmonary TB usually occurs [6, 15]. If extrapulmonary TB develops in 
immunocompetent individuals, no active pulmonary lesions are usually found 
at that time; however, in HIV/AIDS patients disseminated TB is characterized 
by simultaneous involvement of the lungs and other organs [16, 30]. 
Bacterial pneumonia in HIV/AIDS patients occurs at all levels of immuno-
suppression. It may be the fi rst manifestation of HIV infection. Recurrent bacte-
rial pneumonias are not uncommon, and two or more episodes in 12 months 
are considered to defi ne AIDS. Th e etiology of pneumonia in HIV/AIDS is the 
same as in the general population. Streptococcus pneumoniae and Haemo-
philus infl uenzae are predominating. Staphylococcus aureus and Pseudomonas 
aeruginosa are more frequent than in the general population [14, 16, 20].
Immunodefi ciency renders individuals susceptible not only to oppor-
tunistic infections but also to certain malignancies. In HIV/AIDS, malignan-
cies are either AIDS-defi ning (ADM) or non-AIDS-defi ning (NADM). Since 
the introduction of highly active antiretroviral therapy (HAART), the inci-
dence of ADM has decreased, but the incidence of some NADM and the total 
cancer burden in HIV/AIDS population has increased [2, 14]. In comparison 
to general population, additional factors for NADM development in HIV/
AIDS patients are immunosuppression, high rates of oncogenic virus infection 
and the potential oncogenic eff ect of HIV itself [29, 31]. It has been suggested 
that in ADM the severity but in NADM the duration of immunodefi ciency 
play an etiologic role. Th is is supported by the fact that antiretroviral therapy is 
protective against ADM but not against NADM [18, 27, 35].
All ADM are related to oncogenic virus infections (HHV8 to Kaposi 
sarcoma, EBV and/or HHV8 to non-Hodgkin lymphoma, HPV to invasive 
cervical carcinoma). NADM development can also be related to oncogenic 
virus infections (Hodgkin lymphoma – EBV, hepatocellular carcinoma – HCV, 
HBV, anal cancer – HPV) [14, 16]. Rates of infection with these viruses in the 
HIV/AIDS population are high due to shared transmission routes. Increased 
risk for developing lung cancer is attributable to the fact that cigarette smoking 
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is more common, intense and usually initiated at younger age in HIV/AIDS 
patients than in the general population and also to recurrent pulmonary infec-
tions and chronic infl ammation [22].
According to Latvian legislation all patients dying from dangerous infec-
tious diseases including HIV have to undergo autopsy. To our knowledge not 
many autopsy-based studies on morbidity and mortality of HIV/AIDS popu-
lation including large numbers of patients have been performed in Europe, 
including Baltic the countries [3, 7, 22, 36]. 
Th e aim of the study is to evaluate the spectrum, prevalence and morphology 
of pulmonary complications of fatal HIV/AIDS cases in Latvia from 2010–
2016.
MATERIAL AND METHODS
Approval for this study was obtained from the Riga Stradiņš University Ethics 
Committee. Th e study is retrospective and descriptive and was done at the 
Pathology Centre of Riga Eastern Clinical University Hospital. We reviewed 
all the autopsy case fi les of 2010–2016 and selected HIV-positive patients who 
had died in large medical centres in Riga district in that period. From 455 
lethal HIV/AIDS cases, we analysed 380 persons who had lung complications. 
We evaluated the gender, the age at the time of death, pathological and actual 
clinical diagnoses. Th e main diagnosis, complications and comorbidities were 
taken into consideration. We analysed macroscopic organ appearance and 
histological samples. Data on the route of HIV transmission, social status of 
the patient and time of hospitalisation prior to death were collected where 
available. All statistical data were processed in Microsoft  Offi  ce Excel 2007 and 
IBM SPSS Statistics 23.
RESULTS
All the patients included in our study died in Riga district hospitals in seven 
consecutive years. From all 455 patients included in our study, 314 (69.1%) 
were males and 141 (30.9%) were females. In each year that we analysed, the 
numbers of lethal cases among male patients were higher, although during 
the time period encompassed by the study, the numbers of lethal cases among 
female patients increased. 72% of the persons were unemployed at the time of 
death, 9% died in the prison hospital, 9% were disabled and only 10% reported 
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being occupied, although the whole study population was in the working age. 
Hospital stay prior to death ranged from several hours to 280 days (median=10 
days). Th e conditions leading to death included opportunistic infections (28%), 
tuberculosis (23%), malignancies (11%), the end stage of liver disease (11%) 
and wasting syndrome complicated by nonspecifi c pneumonia and sepsis or 
miscellaneous conditions not related to HIV/AIDS (27%). Lungs were aff ected 
in practically all the above-mentioned situations, and there were 380 such cases 
(Table 1).
Analysing fatal opportunistic infections (OI), we found that 28% (n=126) 
of the study population died from them. 77% (n=97) of them had one, and 23% 
(n=29) had two or more OI at the time of death. Th e most common isolated OI 
were Pneumocystis jiroveci pneumonia, isolated pulmonary or CNS as well as 
disseminated cryptococcosis. Th e mean age at the time of death in this patient 
group was equal to that of the study population in general – 40 years (±9 SD, 
range 22–68). Males comprised 65% (n=82) and females 35% (n=44) of this 
group. Most commonly, lungs were aff ected by Pneumocystis jiroveci (PC). 
Th ere were 71 patients (15.6% of the whole study population) with PC pneu-
monia at the time of death. Almost invariably, the gross autopsy fi nding in the 
lethal cases of PC pneumonia was total or subtotal diff use bilateral pulmo-
nary involvement with heavy, expanded, congested lungs. Th e diagnosis was 
Table 1. Lung complications in fatal HIV/AIDS cases in 2010–2016 in Latvia 
Lung involvement Number of cases (n=380)
Tuberculosis 112
Non-specifi c pneumonia 85
Pneumocystis jiroveci pneumonia 71
CMV 40
Criptococcosis 35
Mycobacteriosis avium intracellulare 10
Aspergillosis 5
Candidiasis 5
Secondary lung tumours 5
Primary lung cancer 3
Non-Hodgkin lymphoma 5
Kaposi sarcoma 4
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confi rmed if characteristic PC pneumonia appearance was found on histolog-
ical examination (Fig. 2).
Among various combinations of opportunistic infections, the most common 
was Pneumocystis jiroveci (PC) with cytomegalovirus pneumonia (n=15; 21, 
1% of all PC pneumonias). Th is combination was either isolated (n=12) or 
associated with one more nother opportunistic infection or with tuberculosis 
(n=3). Gross changes were nonspecifi c. On microscopy, characteristic features 
of both pathogens could be visualized.
We found that 40 patients (9% of the study population) had disseminated 
cytomegalovirus (CMV) infection at the time of death as documented in 
clinical charts. CMV infection was also associated with other diseases leading 
to lethal outcomes, most frequently with Pneumocystis jiroveci or nonspecifi c 
pneumonia caused by Streptococcus pneumoniae (Fig. 3).
Among fungal lung infections, we identifi ed cryptococcosis, aspergil-
losis and Candida pneumonia. 47 patients (10% of the study population) had 
crypto coccosis at the time of death. Th ere were 10 cases of isolated pulmonary 
and 25 cases of disseminated cryptococcosis involving either lungs and brain 
or other organs as well as 12 cases of isolated CNS involvement which were not 
included in this research. At gross autopsy examination cryptococcal lesions 
were seen as areas of mucinous tissue lysis. On microscopic examination cryp-
tococcal lesions in lungs appeared as masses of multiple monomorphic round-
oval yeast cells surrounded by clear spaces on haematoxylin eosin staining with 
scarce infl ammatory reactions (Fig. 4). 
From 5 (1% of the study population) cases of aspergillosis, 3 were asper-
gillomas and 2 were cases of bilateral necrotizing aspergillus pneumonia. 
Figure 2. Pneumocystis jiroveci 
pneumonia (H&E, x 100).
Figure 3. Combined Pneumocystis jiroveci and 
Cytomegalovirus pneumonia (H&E, × 400).
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Fatal isolated candidiasis pneumonia was diagnosed in 5 cases (1% of the 
study population). On gross autopsy examination, pulmonary lesions were as 
multiple diff use whitish infi ltrates in diff erent lobes, which are consistent with 
the fact that these patients had candidaemia prior to death as documented in 
clinical charts. Th e diagnoses were confi rmed by identifying fungi within these 
lesions.  
We also identifi ed 10 cases of disseminated “atypical” mycobacteriosis (2% 
of the study population). On gross examination, multiple whitish-yellowish 
miliary lesions with a diameter up to 5 mm were diagnosed in lymph nodes, 
lungs, kidneys, liver, spleen and intestines. Th e diagnosis was accepted if 
 atypical mycobacteriosis was proved by laboratory tests and on histological 
examination non-necrotizing granulomas were identifi ed in aff ected organs. 
In 24.6% (n=112) of the whole study population, we diagnosed a co-infec-
tion with tuberculosis. In 93% (n=104) of all TB cases, the infection was fatal. 
In 21% (n=22) of lethal cases, it was isolated pulmonary TB and in 79% (n=82) 
disseminated but in others with healed tuberculosis of lungs. Males comprised 
78% (n=81) and females 22% (n=23) of the patient group who died from TB. 
Th e mean age at the time of death was 38 years (±8 SD, range 22–59). As calcu-
lated by Levene’s test, there was no statistically signifi cant diff erence in age 
at the time of death between patients with isolated pulmonary and dissemi-
nated TB (level of signifi cance 0.615), which shows that there is no association 
between the HIV/AIDS patients’ age and the tendency to develop disseminated 
TB. According to available information from the clinical charts, in a number of 
cases TB was smear-negative (percentage not shown due to incomplete avail-
ability of clinical data). In a number of patients, TB was diagnosed repeatedly. 
In some of them, it had previously been treated successfully, and some had 
Figure 4. Cryptococcal lesions in lungs 
(H&E, x 100).
Figure 5. Pulmonary tuberculosis 
(H&E, x 100).
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interrupted treatment. In a number of patients, resistance to fi rst-line anti-TB 
medication was reported. On gross autopsy examination, pulmonary TB was 
almost invariably bilateral miliary disseminated (Fig. 5.). In all the cases of 
disseminated TB, multiple uniform miliary lesions were identifi ed in lungs and 
other aff ected organs, most frequently thoracic and abdominal lymph nodes, 
liver, spleen, kidneys and CNS. Caseating lesions up to 0.5 cm in diameter 
were identifi ed in lungs and other organs. Small intestine, pancreas, gonads 
and adrenal glands were involved less frequently. Tuberculous pleuritis and 
peritonitis were also identifi ed in 4 cases. One patient who suff ered from 
endobronchial TB developed a broncho-esophageal fi stula. Both classic and 
atypical histomorphological TB patterns were present among the study popu-
lation. Prevalence of opportunistic infections at the time of death in patients 
who died from any form of TB was 26%, which is the highest among all the 
analysed patient groups. Th e prevalence of OI was higher in patients who died 
from isolated pulmonary TB than in patients who died from disseminated TB. 
Among 22 lethal cases of isolated pulmonary TB, 68% (n=15) had OIs where 10 
of them had one and 5 had two or more OIs at the time of death. And among 
82 lethal cases of disseminated TB, 12% (n=10) had OIs where 9 of them had 
one OI and one patient had a combination of Pneumocystis jiroveci and CMV 
pneumonia. Prevalence of viral hepatitis co-infection in this group was 40%.
As calculated by Spearman’s rank-order correlation test, there was a corre-
lation between the presence of at least one OI that characteristically develops 
at a CD4 count below 200–50 cell/μl at the time of death and a tendency to 
develop TB (p=0.01). Th is points to profound immunosuppression, given also 
the fact that the majority of TB cases were disseminated. Th e patients who had 
TB at the time of death but did not die from it died from end stage liver disease 
decompensation (n=4) and progressive carcinomatous intoxication (n=4). 
We diagnosed 17 (11% of our study population) cases of malignancy which 
had aff ected lungs in the analysed HIV/AIDS cases. Th e malignancy types were 
5 lymphomas and 8 carcinomas: 3 of them primary (2 adenocarcinomas and 
1 squamous cell cancer) but 5 metastatic (from thyroid gland, breast, stomach 
(Fig. 6), liver and pancreas). Th e average age of cancer patients was 46 years. 
Four Kaposi sarcomas aff ected lungs. Th e mean age at the time of death in this 
group was 39 years (±8 SD, range 27–52). Th e group was comprised of 71% 
males and 29% females. Th ere was no statistically signifi cant diff erence in the 
mean age at the time of death from AIDS-defi ning and non-AIDS-defi ning 
malignancies. 
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From 27 cases of lymphomas, lungs were aff ected in 5 cases only. Morpho-
logical and immunohistochemical examination proved that they were 
 non-Hodgkin lymphomas at advanced stages (Fig. 7). Prevalence of oppor-
tunistic infections at the time of death in this group was 15% (n=8), that of 
tuberculosis 7% (n=4), and of viral hepatitis infection 42% (n=22). 
27% (n=122) of study patients died from the wasting syndrome and miscel-
laneous conditions. Th e mean age at the time of death was 40 years (±9 SD, 
range 22–67). 70% (n=86) of this patient group were males and 30% (n=36) 
were females. Almost invariably, these patients had nonspecifi c unilateral or, 
more frequently, bilateral pneumonia, sepsis, septic embolic events as well as 
aspiration and hypostatic pneumonia (n=85). Many of the patients had signs of 
previous episodes of disseminated infectious processes, such as fi brotic changes 
in lungs.
DISCUSSION
If we compare HIV-related statistics of the Baltic states, we can see that the 
rates of new HIV cases in Estonia are approximately the same as in Latvia. But 
the background and dynamics of these data are not the same. Th e high rates of 
new HIV cases in Estonia are due to the active policy of HIV testing not only 
among risk groups but in all individuals of reproductive age [19, 32]. Pulmo-
nary manifestation of HIV can be divided into two groups: patients who have 
received treatment with antiretroviral or chemoprophylactic drugs and those 
who have not [16, 18, 19]. Advanced pulmonary lesions at the time of death 
produced by opportunistic infections that typically develop at a CD4 count 
Figure 6. Gastric carcinoma metastases in 
lung (H&E, ×100).
Figure 7. Diff use large B cell lung lymphoma 
invading myocardium (H&E, ×200).
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below 200 cells/μl indicate that patients are not taking antiretroviral therapy. 
Presence of cases where tuberculosis (TB) was diagnosed repeatedly, fi rst-line 
anti-TB therapy resistance as well as disseminated disease at the time of death 
also indicates poor adherence to both antiretroviral and anti-TB therapy.
Th ere are reports that the prevalence of HIV/TB coinfection is higher in 
intravenous drug users (IVDUs) [15]. In our study, the prevalence of viral 
hepatitis infection in patients who died from TB was 40%, which is typical of 
populations where IVDU is the main HIV transmission route [23], but as it 
was also high in patients who died from other diseases – this only shows that 
IVDU is common among the Latvian HIV/AIDS population. Presence of the 
highest numbers of OIs at the time of death in lethal TB cases and the fact that 
most of TB cases were disseminated indicates profound immunosuppression 
in these patients [2]. 
Early development, aggressiveness and rapid progression of AIDS-defi ning 
lung malignancies (ADM) is attributed to immunosuppression of AIDS, but 
the nature of non-AIDS-defi ning malignancies (NADM) in HIV/AIDS patients 
is not yet understood. In our study, some of the NADM, including lung and 
liver cancers, were diagnosed in HIV/AIDS persons on average some 20 years 
earlier than in the general population and were in more advanced stages [27, 
29]. One theory of these malignancies is that HIV accelerates immunological 
aging and induces genetical instability. Activation of proto-oncogens, altera-
tions in cell cycle regulation, inhibition of tumour suppressor genes, induction 
of micro-satellite instability, induction of pro-angiogenesis signals promotes 
tumour growth and metastasis and makes infected tissues more susceptible 
to oncogenic factors by HIV [31]. In our study population, the prevalence of 
OIs at the time of death in patients dying from NADM was 17%. Th is is rela-
tively low in comparison to the patient group who died from TB. Th is might 
have some something to do with the fact that, besides immunosuppression, 
there may be another pathophysiological mechanism for NADM development. 
Pathologists must take into consideration that, on gross autopsy examination, 
diff erent pathologies of lungs can mimic one another, and conditions that 
usually produce characteristic lesions in tissues can be present in an atypical 
way in HIV/AIDS. 
In the EU, the mean age at the time of HIV diagnosis is 40 years now, while 
according to our results, this is the mean age of death for a Latvian HIV/AIDS 
patient with combined lung pathologies. Th is means that diagnoses of HIV 
in Latvia are established too late when patients are already terminal. While 
in the EU in general, HIV/AIDS patient mortality trends are shift ing towards 
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non-HIV/AIDS-related conditions, this shift  cannot be seen in Latvia, and 
AIDS-related mortality is still high [37].
Already from 2002, there are studies about ART (mainly enfuvirtide (T20) 
and abacavir) as a cause of pneumonia and other respiratory diseases [17, 
21]. Many antiretroviral agents are associated with toxicities and cause drug 
interactions. Around 30% of HIV patients develop an immune reconstitution 
syndrome due to ART [34], and lung lesions are still present in HIV/AIDS 
patients.
Th e population must hope that, in the future, more patients will get ART 
and chemoprophylaxis, and the pulmonary complications of HIV will decrease 
in number. Unfortunately, a large number of persons does not know whether 
they have HIV, and they cannot access care and symptomatic treatment at the 
beginning of the disease. 
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